Jose Baselga

Jose Baselga was a towering figure in HER2-targeted therapy and precision breast oncology who contributed to the development of trastuzumab, pertuzumab, T-DM1, and PI3K inhibitors. His clinical trial work at Memorial Sloan Kettering and Massachusetts General Hospital established the molecular-targeted paradigm for breast cancer treatment. He demonstrated early proof-of-concept for HER2 pathway targeting in clinical studies that defined modern precision oncology. His legacy includes mentorship of generations of breast cancer researchers and the establishment of translational research programs worldwide.